5a8e: Difference between revisions
m Protected "5a8e" [edit=sysop:move=sysop] |
No edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
The | ==thermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol bound== | ||
<StructureSection load='5a8e' size='340' side='right'caption='[[5a8e]], [[Resolution|resolution]] 2.40Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[5a8e]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Meleagris_gallopavo Meleagris gallopavo]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5A8E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5A8E FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.4Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MHA:(CARBAMOYLMETHYL-CARBOXYMETHYL-AMINO)-ACETIC+ACID'>MHA</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=XTK:4-[(2S)-3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY]-7-METHYL-1H-INDOLE-2-CARBONITRILE'>XTK</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5a8e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5a8e OCA], [https://pdbe.org/5a8e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5a8e RCSB], [https://www.ebi.ac.uk/pdbsum/5a8e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5a8e ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/ADRB1_MELGA ADRB1_MELGA] Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Comparisons between structures of the lower case beta1-adrenergic receptor (beta1AR) bound to either agonists, partial agonists or weak partial agonists led to the proposal that rotamer changes of Ser5.46, coupled to a contraction of the binding pocket, are sufficient to increase the probability of receptor activation. Cyanopindolol is a weak partial agonist of beta1AR and, based on the hypothesis above, we predicted that the addition of a methyl group to form 7-methylcyanopindolol would reduce dramatically its efficacy. An eight-step synthesis of 7-methylcyanopindolol was developed and its pharmacology analysed. 7-Methylcyanopindolol bound with similar affinity to cyanopindolol to both beta1AR and beta2AR. As predicted, the efficacy of 7-methylcyanopindolol was dramatically reduced compared to cyanopindolol, acting as a very weak partial of turkey beta1AR and an inverse agonist of human beta2AR. The structure of 7-methylcyanopindolol-bound beta1AR was determined to 2.4 A resolution and found to be virtually identical to the structure of cyanopindolol-bound beta1AR. The major differences in the orthosteric binding pocket are that it has expanded by 0.3 A in 7-methylcyanopoindol-bound beta1AR and the hydroxyl group of Ser5.46 is positioned 0.8 A further from the ligand with respect to the position of the Ser5.46 side chain in cyanopindolol-bound beta1AR. Thus the molecular basis for the reduction in efficacy of 7-methylcyanopindolol compared to cyanopindolol may be regarded as the opposite of the mechanism proposed for the increase in efficacy of agonists compared to antagonists. | |||
Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound beta1-Adrenergic Receptor.,Sato T, Baker J, Warne T, Brown G, Leslie A, Congreve M, Tate C Mol Pharmacol. 2015 Sep 18. pii: mol.115.101030. PMID:26385885<ref>PMID:26385885</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 5a8e" style="background-color:#fffaf0;"></div> | ||
[[Category: Brown | |||
[[Category: | ==See Also== | ||
[[Category: | *[[Adrenergic receptor 3D structures|Adrenergic receptor 3D structures]] | ||
[[Category: Sato | == References == | ||
[[Category: | <references/> | ||
[[Category: Warne | __TOC__ | ||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Meleagris gallopavo]] | |||
[[Category: Baker JG]] | |||
[[Category: Brown GA]] | |||
[[Category: Congreve M]] | |||
[[Category: Leslie AGW]] | |||
[[Category: Sato T]] | |||
[[Category: Tate CG]] | |||
[[Category: Warne T]] | |||
Latest revision as of 14:05, 10 January 2024
thermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol boundthermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol bound
Structural highlights
FunctionADRB1_MELGA Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Publication Abstract from PubMedComparisons between structures of the lower case beta1-adrenergic receptor (beta1AR) bound to either agonists, partial agonists or weak partial agonists led to the proposal that rotamer changes of Ser5.46, coupled to a contraction of the binding pocket, are sufficient to increase the probability of receptor activation. Cyanopindolol is a weak partial agonist of beta1AR and, based on the hypothesis above, we predicted that the addition of a methyl group to form 7-methylcyanopindolol would reduce dramatically its efficacy. An eight-step synthesis of 7-methylcyanopindolol was developed and its pharmacology analysed. 7-Methylcyanopindolol bound with similar affinity to cyanopindolol to both beta1AR and beta2AR. As predicted, the efficacy of 7-methylcyanopindolol was dramatically reduced compared to cyanopindolol, acting as a very weak partial of turkey beta1AR and an inverse agonist of human beta2AR. The structure of 7-methylcyanopindolol-bound beta1AR was determined to 2.4 A resolution and found to be virtually identical to the structure of cyanopindolol-bound beta1AR. The major differences in the orthosteric binding pocket are that it has expanded by 0.3 A in 7-methylcyanopoindol-bound beta1AR and the hydroxyl group of Ser5.46 is positioned 0.8 A further from the ligand with respect to the position of the Ser5.46 side chain in cyanopindolol-bound beta1AR. Thus the molecular basis for the reduction in efficacy of 7-methylcyanopindolol compared to cyanopindolol may be regarded as the opposite of the mechanism proposed for the increase in efficacy of agonists compared to antagonists. Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound beta1-Adrenergic Receptor.,Sato T, Baker J, Warne T, Brown G, Leslie A, Congreve M, Tate C Mol Pharmacol. 2015 Sep 18. pii: mol.115.101030. PMID:26385885[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||